<?xml-stylesheet type='text/xsl' href='ctgovTransform.xsl'?>
<CT.GOV_Trial requestNumber="5924">
  <stage>Registered</stage>
  <submitdate>8/06/2016</submitdate>
  <approvaldate>8/06/2016</approvaldate>
  <nctid>NCT02797522</nctid>
  <trial_identification>
    <studytitle>A Study of ARC-521 Injection in Normal Adult Volunteers and Patients With Chronic Hepatitis B</studytitle>
    <scientifictitle>A Sequential Phase 1a/1b Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Antiviral Activity of ARC-521 in Normal Adult Volunteers and Patients With Chronic Hepatitis B</scientifictitle>
    <utrn />
    <trialacronym />
    <secondaryid>ARC5211001</secondaryid>
  </trial_identification>
  <conditions>
    <healthcondition>Hepatitis B</healthcondition>
    <conditioncode>
      <conditioncode1>Infection</conditioncode1>
      <conditioncode2>Other infectious diseases</conditioncode2>
    </conditioncode>
    <conditioncode>
      <conditioncode1>Oral and Gastrointestinal</conditioncode1>
      <conditioncode2>Other diseases of the mouth, teeth, oesophagus, digestive system including liver and colon</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>Treatment: drugs - ARC-521 Injection
Other interventions - Placebo

Experimental: Healthy Volunteers (NHV) Single Dose - NHV participants receiving a single dose of ARC-521 Injection at doses of 0.6, 1, 2, 4, 5 and 6 mg/kg

Experimental: CHB Patients Multiple Dose - CHB patients receiving 3 doses of ARC-521 Injection at 2, 4 and 6 mg/kg

Placebo Comparator: Placebo - Participants receiving 0.9% normal saline


Treatment: drugs: ARC-521 Injection


Other interventions: Placebo
0.9% normal saline

</interventions>
    <comparator />
    <control />
    <interventioncode>Treatment: drugs</interventioncode>
    <interventioncode>Other interventions interventions</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>Incidence and frequency of adverse events as a measure of the safety and tolerability of single doses of ARC-521 Injection</outcome>
      <timepoint>Baseline to Day 29 (Healthy Volunteers)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Incidence and frequency of adverse events as a measure of the safety and tolerability of multiple doses of ARC-521 Injection</outcome>
      <timepoint>Baseline to Day 85 (Healthy Volunteers; Baseline to Day 142 (CHB patients)</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - AUC0-24: Change over time (NHVs only) - Area under the plasma-concentration-time curve from time 0-24 hours</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - AUC last: Change over time (NHVs only) - Area under the plasma-concentration-time curve from time 0 to the last quantifiable plasma concentration</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - AUCinf: Change over time (NHVs only) - Area under the plasma-concentration-time curve from time 0 extrapolated to infinity</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - Cmax: Change over time (NHVs only) - Maximum observed plasma concentration</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - CL: Change over time (NHVs only) - Clearance</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - V: Change over time (NHVs only) - Apparent volume of distribution</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - kel: Change over time (NHVs only) - Terminal elimination rate constant</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Pharmacokinetics of ARC-521 Injection - t1/2: Change over time (NHVs only) - Terminal elimination half-life</outcome>
      <timepoint>Through 48hrs post-dose</timepoint>
    </primaryOutcome>
    <primaryOutcome>
      <outcome>Change over time in viral antigens and DNA in CHB patients as a measure of activity of ARC-521 Injection</outcome>
      <timepoint>Baseline to Day 142</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>Change over time in cytokine levels after single and multiple doses of ARC-521 Injection</outcome>
      <timepoint>Through 24 hours post-dose (Day 1 for NHVs, and Days 1, 29 &amp; 57 for CHB patients)</timepoint>
    </secondaryOutcome>
    <secondaryOutcome>
      <outcome>Change over time in complement levels after single and multiple doses of ARC-521 Injection</outcome>
      <timepoint>Through 24 hours post-dose (Day 1 for NHVs, and Days 1, 29 &amp; 57 for CHB patients)</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-  Male or female, 18 to 55 years of age inclusive [NHVs] or 18-65 years of age inclusive
             [CHBs], at the time of informed consent

          -  Able to provide written informed consent prior to the performance of any study
             specific procedures

          -  Body mass index (BMI) between 19.0 and 35.0 kg/m2, inclusive

          -  A 12-lead ECG at Screening and pre-dose assessment that, in the opinion of the
             investigator, has no abnormalities that compromise participant's safety in this study

          -  Must use 2 effective methods of contraception (double barrier contraception or
             hormonal contraceptive along with a barrier contraceptive (both male and female
             partners)

          -  Have suitable venous access for blood sampling

          -  No abnormal finding of clinical relevance at the Screening evaluation [NHVs only]

          -  Have a diagnosis of HbeAg negative Chronic HBV infection [CHB patients only]

          -  Treatment naive or currently on entecavir/tenofovir for 6 months or longer</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>65</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>-  Pregnant or lactating

          -  Acute signs of hepatitis/other infection at Screening or at baseline

          -  Use within last 14 days or anticipated requirement for anticoagulants, systemic
             corticosteroids, immunomodulators, or immunosuppressants

          -  Use of prescription medication within 14 days prior to study treatment that in the
             opinion of the PI or the Sponsor would interfere with study conduct.

          -  Known diagnosis of non-alcoholic steatohepatitis [NHVs only] or familial
             hypercholesterolemia

          -  Taking interferon alpha (INFalpha) within 6 months of screening [CHBs only]

          -  History of poorly controlled autoimmune disease or history of autoimmune hepatitis

          -  Human immunodeficiency virus (HIV) infection

          -  Seropositive for Hepatitis B Virus (HBV) [NHVs only] or Hepatitis C Virus (HCV),
             and/or history of delta virus hepatitis

          -  Hypertension defined as blood pressure &gt; 170/100 mmHg at screening [NHVs only]

          -  A history of cardiac rhythm disturbances

          -  Family history of congenital long QT syndrome, Brugada syndrome or unexplained sudden
             cardiac death

          -  Symptomatic heart failure, unstable angina, myocardial infarction, severe
             cardiovascular disease within 6 months prior to study entry

          -  History of malignancy within the last 5 years except for adequately treated basal cell
             carcinoma, squamous cell skin cancer, superficial bladder tumors, or in situ cervical
             cancer

          -  History of major surgery within 3 months of Screening

          -  Regular use of alcohol within one month prior to the Screening visit (more than
             fourteen units of alcohol per week)

          -  Evidence of severe systemic acute inflammation, sepsis, or hemolysis [NHVs only]

          -  Use within 3 months of illicit drugs (cocaine, phencyclidine [PCP],
             3,4-methylenedioxymethamphetamine [MDMA], others) or positive test for drugs of abuse
             at screening.

          -  History of allergy to bee venom or history of severe hypersensitivity reaction, such
             as anaphylaxis

          -  Use of an investigational agent or device within 30 days prior to dosing or current
             participation in an investigational study

          -  Clinically significant history of any alcoholic liver disease, cirrhosis, Wilson's
             disease, hemochromatosis, or alpha-1 antitrypsin deficiency, liver or kidney disease

          -  Clinically significant history/presence of poorly controlled or decompensated
             neurological, endocrine, cardiovascular, pulmonary, hematological, immunologic,
             psychiatric, metabolic, or other uncontrolled systemic disease

          -  Blood donation (500 mL) within 7 days prior to study treatment administration [NHVs
             only]

          -  History of fever (&gt;38.0ºC/100.4ºF) within 2 weeks of Screening [NHVs only]

          -  Any concomitant medical or psychiatric condition or social situation that impacts
             compliance or involves additional safety risk

          -  History of coagulopathy (including deep vein thrombosis and pulmonary embolism) or
             stroke within 6 months of baseline, and/or concurrent anticoagulant medication(s)

          -  Presence of cholangitis, cholecystitis, cholestasis, or duct obstruction</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking>Blinded (masking used)</masking>
    <assignment>Parallel</assignment>
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1>The people receiving the treatment/s</masking1>
    <masking2>The people administering the treatment/s</masking2>
    <masking3>The people assessing the outcomes</masking3>
    <masking4>The people analysing the results/data</masking4>
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase>Phase 1</phase>
    <anticipatedstartdate />
    <actualstartdate>1/06/2016</actualstartdate>
    <anticipatedenddate />
    <actualenddate />
    <samplesize />
    <actualsamplesize>47</actualsamplesize>
    <recruitmentstatus>Terminated</recruitmentstatus>
    <anticipatedlastvisitdate />
    <actuallastvisitdate>1/11/2016</actuallastvisitdate>
    <dataanalysis />
    <withdrawnreason />
    <withdrawnreasonother />
    <recruitmentcountry />
    <recruitmentstate />
    <countryoutsideaustralia>
      <country>New Zealand</country>
      <state>Auckland</state>
    </countryoutsideaustralia>
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Arrowhead Pharmaceuticals</primarysponsorname>
    <primarysponsoraddress />
    <primarysponsorcountry />
  </sponsorship>
  <ethicsAndSummary>
    <summary>Normal healthy volunteers (NHVs) will enroll sequentially into a total of 6 escalating dose
      levels randomized to receive ARC-521 Injection or placebo.

      Hepatitis B e Antigen (HBeAg) negative Chronic Hepatitis B patients (CHBs) will enroll
      sequentially into a total of 3 dose levels to receive open-label ARC-521 Injection.</summary>
    <trialwebsite>https://clinicaltrials.gov/show/NCT02797522</trialwebsite>
    <publication />
    <ethicsreview />
    <publicnotes />
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Public Queries</type>
    </contact>
  </contacts>
</CT.GOV_Trial>